Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers

Asthma Clinical Trial

Official title:

Symptom-driven Combination Inhaled Corticosteroids and Long-acting Beta Agonist Therapy for Patients With Asthma Who Are Identified as Non-adherent to Daily Maintenance Inhalers

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05111262
• Other study ID #: 202108173
• Secondary ID: KL2TR002346UL1TR
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: December 16, 2021
• Est. completion date: December 30, 2023

Study information

• Verified date: March 2023
• Source: Washington University School of Medicine
• Contact: Abigail Zulich
• Phone: 314-747-3063
• Email: azulich[@]wustl.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Inhaler nonadherence is a common problem that has been estimated to account for approximately 60% of all asthma-related hospitalizations. Unfortunately, prior interventions to improve inhaler nonadherence have shown a lack of long-term success. This study proposes to assess the problem of non-adherence using a D&I research lens while testing a new inhaler approach to potentially ameliorate the detrimental consequences of maintenance inhaler nonadherence.

Description:

While inhaled corticosteroids (ICS) are considered the essential foundation of most asthma therapy, ICS inhaler non-adherence is a notoriously common problem and a significant cause of asthma-related morbidity. Partially acknowledging the problem of non-adherence, international organizations recently made paradigm-shifting recommendations that all patients with mild or mild-to-moderate persistent asthma be considered for symptom-driven ICS-containing inhalers rather than relying on adherence to traditional maintenance ICS inhalers and symptom-driven beta-agonists. With this novel approach, asthma patients are at least exposed to the important anti-inflammatory effects of ICS-containing inhalers when their inhaler is deployed due to symptoms. The proposed study aims to (Aim 1) undertake a pragmatic pilot randomized-controlled trial to evaluate if an inhaler strategy that utilizes symptom-driven ICS inhalers is particularly accepted and beneficial in maintenance ICS inhaler non-adherent asthma patients, and (Aim 2) use a D&I science conceptual framework to better understand patients' and providers' views of inhaler non-adherence. This study will use an electronic sensor to monitor inhaler adherence and include semi-structured interviews using the Consolidated Framework for Implementation Research (CFIR).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: December 30, 2023
• Est. primary completion date: November 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Able to understand and provide informed consent.

2. Age 12-75 at the time of study enrollment.

3. Provider diagnosed mild or moderate persistent asthma and prescribed maintenance ICS treatment and as needed SABA for at least 6 months prior to enrollment.

4. Suboptimal adherence to prescribed maintenance ICS therapy defined as missing at least expected 2 ICS refills in the prior 6 months based on examination of pharmacy records or a Medication Adherence Report Scale for Asthma (MARS-A) score <4.5.

5. An Asthma Control Test (ACT) score at enrollment greater than or equal to 12 but less than or equal to 20 indicating partially controlled or moderately uncontrolled asthma. Adolescents age 12-17 with an ACT score 12-25 will be considered eligible.

6. iPhone or Android smartphone with an active data plan and willingness to use the Adherium device.

Exclusion Criteria:

1. Relevant comorbid pulmonary diseases including, but not limited to a diagnosis of chronic obstructive pulmonary disease (COPD), cystic fibrosis, or alpha 1 anti-trypsin deficiency.

2. Current use of a biologic medication or investigational treatment for asthma.

3. History of asthma requiring ICU admission in the last year.

4. Unwillingness to use or pay for an inhaler that is compatible with the Adherium sensor (fluticasone propionate or budesonide/formoterol). Of note, fluticasone and budesonide/formoterol are formulary tier 1-2 for Missouri Medicaid and most commercial insurances and are believed to be equally or less expensive as alternative inhalers for most patients.

5. Any clinically significant abnormalities on physical exam, laboratory testing, or baseline diagnostic testing that the study team believes will make the study unsafe.

6. Patients who do not complete at least 70% of the twice-daily texts during the two weeks after screening.

Related Conditions & MeSH terms

• Asthma
• Nonadherence, Medication

Intervention

Drug:
• Adherence to symptom driven budesonide/formoterol as compared to adherence to maintenance ICS and symptom-driven SABA
In this study, we propose a pragmatic, pilot, open-label trial where we are comparing adherence to different inhaler regimens. Patients who were previously sub-optimally adherent to maintenance ICS inhalers will either continue receiving maintenance ICS inhalers and symptom-driven SABA inhalers or symptom-driven ICS/LABA inhalers only.

Locations

Country	Name	City	State
United States	Washington University in St. Louis School of Medicine	Saint Louis	Missouri

Sponsors (3)

Lead Sponsor	Collaborator
Washington University School of Medicine	National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adherence to inhaler strategy delineated using an electronic inhaler sensor	The primary outcome will be adherence with an inhaler management strategy delineated using the Adherium inhaler sensor and smartphone application as compared between groups. Adherence to the treatment strategy for the maintenance ICS inhaler group will be calculated as the proportion of maintenance ICS actuations per prescription recommendation. Adherence for the symptom-based ICS treatment strategy will be calculated as the proportion of ICS/LABA actuations per recommendation based on self-report of symptoms (definition: ICS/LABA inhaler actuation during a day or night period divided by a period wherein a patient identified symptoms as >1 on REDCap-delivered smartphone questionnaire).	24 weeks
Secondary	Number of asthma exacerbations	Frequency of study-defined asthma exacerbations between groups (adjusted for time on treatment). Asthma exacerbations will be defined as an urgent medical visit for asthma symptoms, prescription of oral corticosteroids for asthma symptoms, or high use of a rescue inhaler (>16 actuations of SABA or >8 actuations of ICS/LABA within 24 hours on two consecutive days as assessed via the Adherium device).	24 weeks
Secondary	Time to asthma exacerbation	Time to first exacerbation between groups. Asthma exacerbations will be defined as an urgent medical visit for asthma symptoms, prescription of oral corticosteroids for asthma symptoms, or high use of a rescue inhaler (>16 actuations of SABA or >8 actuations of ICS/LABA within 24 hours on two consecutive days as assessed via the Adherium device).	24 weeks
Secondary	ICS exposure	Converted cumulative dose of ICS between groups.	24 weeks
Secondary	Adverse and serious adverse events	Occurrence of any severe and non-severe adverse events between groups.	24 weeks
Secondary	Change in Asthma Control Questionnaire (ACQ)	Change in Asthma Control Questionnaire (ACQ) from baseline to the final study visit.	24 weeks
Secondary	Change in asthma control test (ACT)	Change in Asthma Control Test (ACT) from baseline to the final study visit.	24 weeks
Secondary	Change in Asthma Quality of Life Questionnaire (AQLQ)	Change in Asthma Quality of Life Questionnaire (AQLQ) from baseline to the final study visit.	24 weeks
Secondary	Change in Medication Adherence Reporting Scale for Asthma (MARS-A) questionnaire	Change in Medication Adherence Reporting Scale for Asthma (MARS-A) questionnaire from baseline to the final study visit.	24 weeks
Secondary	Change in IQVIA Treatment Satisfaction Questionnaire for Medication (TSQM)	Change in IQVIA Treatment Satisfaction Questionnaire for Medication (TSQM) from baseline to the final study visit.	24 weeks
Secondary	Change in The Knowledge, Attitude, and Self-Efficacy Asthma Questionnaire (KASEAQ)	Change in The Knowledge, Attitude, and Self-Efficacy Asthma Questionnaire (KASEAQ) from baseline to the final study visit.	24 weeks
Secondary	Change in Feeling of Satisfaction with Inhaler (FSI-10) questionnaire	Change in Feeling of Satisfaction with Inhaler (FSI-10) questionnaire from baseline to the final study visit.	24 weeks